Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.76 |
| ▸ | GAA | P10253 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | UBE2N | P61088 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12453045 | 0.80 | MEN1 (0.70) | GAAALDH1A1HTTKMT2ATSHR | |
| SCHEMBL31195203 | 0.75 | L3MBTL1 (0.72) | GAAALDH1A1KMT2AMAPT | |
| SCHEMBL5237448 | 0.74 | HPGD (1.00) | MAPK1GAAALDH1A1HTTKMT2A | |
| SCHEMBL11624141 | 0.73 | KMT2A (0.83) | MAPK1GAAALDH1A1HTTKMT2A | |
| SCHEMBL11626214 | 0.71 | HPGD (0.73) | MAPK1GAAALDH1A1HTTKMT2A | |
| SCHEMBL4123540 | 0.71 | L3MBTL1 (1.00) | MAPK1ALDH1A1KMT2AHPGDMAPT | |
| SCHEMBL12793423 | 0.71 | L3MBTL1 (0.69) | ALDH1A1KMT2AHPGDMAPT | |
| SCHEMBL14198603 | 0.71 | KMT2A (0.79) | GAAALDH1A1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL11621200 | 0.70 | KMT2A (0.76) | MAPK1ALDH1A1KMT2ASMN1; SMN2HPGD | |
| SCHEMBL19990364 | 0.70 | KDM4E (0.72) | GAAALDH1A1KMT2ARXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270263-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-08-27 | — | — | US | disclosed |
| US-10689392-B2 | Anti-cancer compounds targeting ral GTPases and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-06-23 | — | — | US | disclosed |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2016-09-29 | — | — | US | disclosed |
| US-9353121-B2 | Anti-cancer compounds targeting Ral GTPases and methods of using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-05-31 | — | — | US | disclosed |
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2013096820-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315894-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | MAPK1 1781/4885GAA 1980/4885ALDH1A1 3045/4885 |
| US-20160280715-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | MAPK1 1781/4885GAA 1980/4885ALDH1A1 3045/4885 |
| US-10689392-B2 | Anti-cancer compounds targeting ral GTPases and methods of using the same | ARFGAP1, ARHGDIB, IQGAP1 | MAPK1 1781/4885GAA 1980/4885ALDH1A1 3045/4885 |
| US-20200270263-A1 | ANTI-CANCER COMPOUNDS TARGETING RAL GTPASES AND METHODS OF USING THE SAME | ARFGAP1, ARHGDIB, IQGAP1 | MAPK1 1781/4885GAA 1980/4885ALDH1A1 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.